Atai Life Sciences (ATAI) said Tuesday the results of a phase 2a study of Beckley Psytech's BPL-003 in patients with moderate to severe alcohol use disorder were encouraging.
The open-label study involved 12 patients, who were given a single dose of BPL-003, in combination with relapse prevention cognitive behavioral therapy, the company said.
The combination resulted in "meaningful and sustained reduction in alcohol use and heavy drinking days" in the 12-week study, it said.
BPL-003 also demonstrated a favorable safety profile, with adverse events characterized as mild or moderate, Atai said.
Beckley Psytech is partly own by Atai.
Atai shares were down more than 3% in recent trading.
Price: 1.40, Change: -0.05, Percent Change: -3.45
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。